UCLi012-A
General
Cell Line |
|
hPSCreg name | UCLi012-A |
Cite as: | UCLi012-A (RRID:CVCL_WT96) |
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
CENSOi003-B (FB79R2c6, CENSOi258) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi005-A (FB76R2c5, CENSOi245) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi007-A (FB75R2c5, CENSOi255) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi001-B (FB78R2c2, CENSOi249) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi002-B (FB74R2c4, CENSOi261) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy UCLi006-A (LCMD-L302P-UCL01C2) Donor's gene variants: LMNA Donor diseases: Congenital muscular dystrophy due to LMNA mutation UNEWi026-A (SF116 clone 1) Donor's gene variants: CFH Donor diseases: type 2 diabetes mellitus age-related macular degeneration UNEWi026-B (SF116 clone 2) Donor's gene variants: CFH Donor diseases: type 2 diabetes mellitus age-related macular degeneration UNEWi026-C (SF116 clone K) Donor's gene variants: CFH Donor diseases: type 2 diabetes mellitus age-related macular degeneration UKBi003-A (iLB-MJD1-32m-r9, LB-32-r9) Donor's gene variants: ATXN3, ATXN3 Donor diseases: Machado-Joseph disease UKBi008-A (iLB-MJD4-34m-r1, LB-34-1) Donor's gene variants: ATXN3, ATXN3 Donor diseases: Machado-Joseph disease |
Last update | 22nd May 2019 |
User feedback | |
Provider |
|
Generator | University College London (UCL) |
External Databases |
|
BioSamples | SAMEA5574041 |
Cellosaurus | CVCL_WT96 |
Wikidata | Q98133849 |
General Information |
|
Publications |
|
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
Sex | male |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
BioSamples | SAMEA5727782 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | No |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | No information |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | NHS Health Research Authority |
Approval number | Research Ethics Committee reference no. 06/Q0406/33 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | NHS Health Research Authority |
Approval number | Research Ethics Committee reference no. 13/LO/1826; IRAS project ID: 141100 |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
Any skin fibroblast that is part of some dermis.
|
Reprogramming method |
|
Vector type | None |
Vector free reprogramming |
|
Type of used vector free reprogramming factor(s) |
mRNA
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Surface coating | Vitronectin |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
O2 Concentration | 3 % |
CO2 Concentration | 5 % |
Medium |
TeSR™ E8™
|
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
NANOG |
Yes |
|||||
SOX2 |
Yes |
|||||
POU5F1 (OCT-4) |
Yes |
Morphology pictures
TRA-1-60 live staining
Method documentation
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
46, XY
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.